Category: 2024 PR

Posted on / by Ante / in 2024 PR

Promising preclinical proof of efficacy for the GP VI antibody

Dallas, Texas, Düsseldorf and Martinsried, Germany, 07. November 2024: A seminal paper about the role of GPVI in vascular aneurysma and successful therapeutic intervention with an anti-GPVI antibody in abdominal aortic aneurysma was published from our group together with colleagues from the Düsseldorf University in the AHA Journal Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB).
Posted on / by Ante / in 2024 PR

Positive FDA Guidance for Phase III received for Revacept

Silver Springs, Maryland, and Martinsried, Germany, 07. August 2024: The U.S Food and Drug Association (FDA) has reviewed the preclinical and clinical development program for Revacept / PR-15 in a Type C meeting. Further on, the future clinical development program until market approval was presented and discussed with the FDA.